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ABSTRACT 
The aim of this systematic review with meta-analysis was evaluate the effect on length of labor 
when patients receive IVF with or without dextrose. Searches were performed in electronic 
databases from inception of each database to May 2018. Trials comparing intrapartum IVF 
containing dextrose (i.e. intervention group) with no dextrose or placebo (i.e. control group) 
were included. Only trials examining low-risk pregnancies in labor at ≥36 weeks were included. 
Studies were included regardless of oral intake restriction. The primary outcome was the length 
of total labor from randomization to delivery. The meta-analysis was performed using the 
random effects model. Sixteen trials (n=2,503 participants) were included in the meta-analysis. 
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Women randomized in the IVF dextrose group did not have a statistically significant different 
length of total labor from randomization to delivery compared to IVF without dextrose (MD -
38.33 minutes, 95% CI -88.23 to 11.57). IVF with dextrose decreased the length of the first stage 
(MD -75.81 minutes, 95% CI -120.67 to -30.95), but there was no change in the second stage. In 
summary, use of IVF with dextrose during labor in low-risk women at term does not affect total 
length of labor, but it does shorten the first stage of labor. 
Keywords: cesarean delivery; intravenous fluid; labor; operative delivery; vaginal delivery 
Abbreviations: CD, cesarean delivery; SVD, spontaneous vaginal delivery; DM, diabetes mellitus; GDM, gestational 
diabetes mellitus; h, hour; OVD, operative vaginal delivery; IOL, induction of labor; IUGR, intrauterine growth 
restriction; IVF, intravenous fluid; GA, gestational age; NR, not reported; HR, heart rate; IFD, intrauterine fetal 
death 
 
Keywords: cesarean delivery, intravenous fluid, labor, operative delivery, vaginal delivery 
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INTRODUCTION 
Length of labor may be a determinant of the health of both mother and neonate. Longer 
lengths of labor have been shown to be associated with increased rate of cesarean delivery, 
chorioamnionitis, and admission to the neonatal intensive care unit (NICU).1 Diminished uterine 
contractile strength serves a role in prolonging labor, given the oxytocin augmentation.2 
Therefore, identifying interventions that safely decreases the length of labor is beneficial.3,4 In 
many countries, patients receive intravenous fluids during induction or labor management.  One 
meta-analysis of randomized controlled trials (RCTs) showed that a policy of intrapartum 
intravenous fluid (IVF) rate of 250 mL/hr is associated with a reduction in length of labor 
compared to a policy of 125 mL/hr.3 Because carbohydrate replacement helps muscle 
performance during prolonged exercise,3 it has been hypothesized that carbohydrate replacement 
may enhance the function of the contracting uterus, and speed up the laboring process. Recent 
studies have found no significant changes in fetal acid-base status when utilizing IVF with 
dextrose4–6. However, administration of IVF with dextrose during labor is unclear as the size of 
cohorts in original studies prevents generalizability and the findings are mixed.  
Thus, the aim of this systematic review and meta-analysis of RCTs was to evaluate the 
effect on length of labor of IVF with or without dextrose as well as to examine the effects of IVF 
with dextrose on other maternal and neonatal outcomes.  
METHODS  
Eligibility criteria, information sources, search strategy 
This review was performed according to a protocol designed a priori by the investigators 
and recommended for systematic review and meta-analysis.7 Searches were performed 
independently by two authors (MR, JQN) in Medline, OVID, Scopus, ClinicalTrials.gov, 
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Embase, and the Cochrane Library. Appendix S1 shows the search strategy for this review that 
can be replicated to verify or update the results. Keywords were searched from inception of each 
database to October 2017. No restrictions for language or geographic location were applied.  
Study selection 
RCTs comparing intrapartum IVF with dextrose (i.e. intervention group) versus IVF with 
no dextrose or placebo (i.e. control group) were included in the meta-analysis. Only trials on 
low-risk women (as defined by individual studies) in labor at ≥36 weeks were included. Studies 
were included regardless of whether or not oral intake was restricted and irrespective of the type 
of IVF used. Augmentation of labor with oxytocin was not considered a criterion for exclusion. 
Trials including high-risk pregnant women (e.g. women with diabetes, preeclampsia, neonates 
with intrauterine growth restriction) were excluded. We planned to include only trials in which 
IVF were administered during labor, as this intervention has been proven to be effective. Titles 
and abstracts for all identified studies were independently reviewed by two reviewers (MR, 
JQN). Any disagreements were resolved with discussion with a third reviewer (VB).   
Data extraction 
The primary outcome was the total length of labor from randomization to delivery. Pre-
specified secondary outcomes were length of labor from randomization to complete dilation (first 
stage), length of labor from complete dilatation to delivery (second stage), mode of delivery, 
augmentation of labor, chorioamnionitis, postpartum haemorrhage, and neonatal outcomes. 
Neonatal outcomes included Apgar <7 at 5 minutes, neonatal hypoglycemia (serum glucose <40 
mg/dL), admission to NICU, and neonatal blood gas parameters at delivery (umbilical artery pH, 
CO2, O2, and base deficit). 
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We planned to assess the primary outcome (i.e. length of labor from randomization to 
delivery) in the following subgroup analyses: 
1) According to the amount of dextrose 
2) According to the rate of fluids used 
3) According to restriction of oral fluid intake 
We also planned to perform a sensitivity test including only trials, which blinded 
participants to type of IVF.  Only the primary outcome was assessed in subgroup and sensitivity 
analyses. 
Assessment of risk of bias 
The risk of bias for each trial was assessed by using the criteria outlined in the Cochrane 
Handbook for Systematic Reviews of Interventions. Seven domains related to risk of bias were 
assessed in each included trial since there is evidence that these issues are associated with biased 
estimates of treatment effect: 1) random sequence generation; 2) allocation concealment; 3) 
blinding of participants and personnel; 4) blinding of outcome assessment; 5) incomplete 
outcome data; 6) selective reporting; and 7) other bias. Review authors’ judgments were 
categorized as “low risk”, “high risk” or “unclear risk” of bias.7 
Data synthesis 
The data analysis was completed independently by two authors (MR, GS) using Review 
Manager 5.3 (Copenhagen: The Nordic Cochrane Centre, Cochrane Collaboration, 2014). The 
completed analyses were then compared and any difference was resolved by discussion with a 
third reviewer (VB). Meta-analysis was performed using the random effects model of 
DerSimonian and Laird, to produce summary treatment effects in term of mean difference (MD) 
or relative risk (RR) with 95% confidence interval (CI). Heterogeneity across studies was 
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assessed using the Higgins I2 test. Potential publication biases were assessed statistically by 
using Begg’s and Egger’s tests.7  The meta-analysis was reported following the Preferred 
Reporting Item for Systematic Reviews and Meta-analyses (PRISMA) statement. The review 
was registered with the PROSPERO International Prospective Register of Systematic Reviews 
(Registration Number: CRD42017079583).   
RESULTS 
Study selection and study characteristics  
 Sixteen trials were included in the meta-analysis (Figure 1).8–13,4,14–17,6,5,18–20 A total of 
2,503 nulliparous and multiparous women in spontaneous or induced labor at term were included 
(Table 1). Of the 2,503 women included, 1,271 (50.8%) were in the dextrose group (i.e. 
intervention group), and 1,232 (49.2%) in the no dextrose group (i.e. control group). All studies 
that reported this baseline characteristic included only singleton gestations. Of the 14 studies that 
reported this variable, seven (50%) included women in spontaneous labor, five (36%) included 
women in spontaneous or induced labor, and two (14%) included only women with induction of 
labor. When reported, cervical dilatation at enrollment was ranged from 3-5cm (Table 1). In the 
dextrose group, twelve studies used 5% dextrose, two studies8,9 used 5% and 10% dextrose, one 
study 10% dextrose,10 and one study used 2.5% and 5% dextrose.11 Regarding the no dextrose 
(control) group, the majority of the studies (fourteen in total) used 0.9% normal saline solution or 
lactated Ringer’s solution. Two studies used more than one control group, one with lactated 
Ringer’s solution and no IVF, and the other with lactated Ringer’s solution and 0.9% normal 
saline.8,13  IVF infusions were administered at varying rates, from 20-300 mL/h (Table 2). IVF 
were generally initiated during ‘active labor’. In one study that included induction of labor only, 
IVF were initiated with oxytocin.4 Oxytocin use was significant less for the IVF with dextrose 
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compared to the IVF without dextrose. There were no significant differences in the incidences of 
induction, nulliparity, or epidural use, between dextrose vs no dextrose groups (Table 3). 
Individual patient data meta-analysis, while ideal, was not undertaken secondary to the limited 
response of the individual authors in providing data. 
The majority of included trials were judged as low risk of bias (Figure 2). Three articles 
did not follow the principle of intention to treat, increasing the risk of attrition bias.14,16,17 These 
articles received a high risk of bias as they excluded previously randomized patients from the 
final analysis if they underwent induction of labor or operative vaginal delivery. Figure 3 shows 
the funnel plot for assessing publication bias. Publication bias, assessed using Begg’s and 
Egger’s tests, showed no significant bias (P=0.34 and P=0.33, respectively). Statistically 
heterogeneity was high, I2=82% for the primary outcome.  
Synthesis of results 
There was no significant difference in total length of labor (MD -38.33 minutes, 95% CI -
88.23 to 11.57; 8 studies; 1,501 participants; I2=82%; Figure 3) or second stage of labor (MD -
7.63 minutes, 95% CI -19.80 to 4.54; 6 studies; 1,298 participants; I2=91%; Table 4) between 
women who received dextrose and those who did not. However, women who received dextrose 
had a significantly shorter first stage of labor (MD -75.81 minutes, 95% CI -120.67 to -30.95; 4 
studies; 873 participants; I2=84%). Chorioamnionitis, prolonged labor >12 hours, and postpartum 
haemorrhage occurred at similar rates in the two groups. Most (over three quarters) women had 
vaginal deliveries, with similar incidence in the two groups, and there was no significant 
difference in operative vaginal delivery (Table 5). AC
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Regarding neonatal outcomes, there were no statistically significant differences in Apgar 
scores, hypoglycemia, or admission to NICU (Table 6). Umbilical arterial and venous gases were 
recorded in 6 of the 16 trials and there were no significant changes between groups (Table 7).21 
Subgroup and sensitivity analyses 
The following subgroup analyses concurred with the overall analysis with no significant 
differences for the primary outcome: 
1) Only RCTs using 5% dextrose: MD -14.72 minutes, 95% CI -63.15 to 33.73 
2) Only RCTs with unrestricted policy for oral intake: MD -43.50 minutes, 95% CI -
95.46 to 8.45 
3) When including only RCTs that blinded participants to type of IVF: MD -78.30 
minutes, 95% CI -86.82 to -69.78 
Subgroup analysis for only trials using IVF rate at > 125 mL/h (MD -97.82 minutes, 95% CI -
184.08 to -11.55), and sensitivity analysis including only double-blind trials (MD -67.97 
minutes, 95% CI -112.93 to -11.01) showed significant benefit in the dextrose group with a 
significant reduction in the length of labor. 
DISCUSSION  
Main Findings 
This meta-analysis of RCTs, evaluating the effectiveness of IVF with dextrose compared 
to no dextrose, demonstrated no difference in total length or second stage of labor. There was a 
reduction in first stage of labor. Since this is the longest stage of labor, this finding may indicate 
there is some benefit to utilizing IVF with dextrose in laboring women. This is to be interpreted 
with caution as the length of first stage of labor is defined differently between studies, as some 
did not specify the period that the patient was in active labor. Moreover, in the best quality (e.g. 
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blinded RCTs), the duration of the total length of labor was statistically different. The addition of 
dextrose to IVF was also associated with a trend (but no significance) for lower incidence of 
labor lasting >12hours. 
Although the increased rate of hypoglycemia had a confidence interval that crossed 1.0, 
the RR (95% CI) of 2.25 (0.94, 5.35) there is a trend towards significance. Therefore, it would be 
prudent to observe neonates exposed to maternal dextrose containing fluids for signs and 
symptoms of hypoglycemia after delivery until an appropriately powered study confirms whether 
the risk is clinically important. There are no significant changes in neonatal umbilical artery gas 
results, suggesting that exposure to dextrose in labor does not lead to a compromised infant.   
Strengths and Limitations 
 Our study has several strengths. To our knowledge, this is the first meta-analysis 
comparing IVF with dextrose vs no dextrose. The included trials were all RCTs and all examined 
dextrose administration while in labor, and our primary outcome includes 8 studies with 1,501 
participants. Limitations of our study are inherent to the limitations of a meta-analysis and the 
included studies. There were discrepancies between studies, as some excluded women who had 
operative deliveries or induction of labour.11,14–17,6 As this is not an individual patient data meta-
analysis, we are unable to differentiate laboring vs induction, cervical dilation at time of 
presentation, and indication for operative vaginal delivery. One study allowed women to freely 
eat and drink throughout labor, which may have affected our outcome variables.4 In general, 
there were several secondary outcomes not addressed in various studies. Fluid management is 
only one aspect of labor management and there may be other confounders driving these findings. 
In original trials is difficult to define the duration of the first stage of labor. There was lack of 
data regarding lactate concentrations in cord blood. 
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Interpretation 
Different meta-analyses have been published to assess the efficacy of different technique 
during labor aimed to reduce the length of labor.22-30 Our meta-analysis appears to be the first to 
study RCTs strictly comparing IVF with dextrose versus no dextrose. Previous studies have 
demonstrated the ability of an IVF rate of 250 mL/hr to shorten length of labor compared to IVF 
rate of 125mL/hr, but did not address dextrose administration.22,23 In one meta-analysis, an 
included RCT utilized normal saline in dextrose water, but the authors did not compare dextrose 
versus no dextrose in the study population.24 Another meta-analysis could not reach a conclusion 
regarding the efficacy of dextrose or its impact on length of labour.25 The studies included in our 
meta-analysis were heterogeneous as they included both laboring and induced patients, making it 
more generalizable to a labor and delivery floor. However, without the ability to perform an 
individual patient level meta-analysis, we were unable to see if particular groups would benefit 
from IVF with dextrose.  
CONCLUSION 
The addition of dextrose to IVF appears to shorten the duration of first stage of labor, and 
the total length of labor in the best quality studies, but not in the overall analysis, for low-risk 
laboring nulliparous and multiparous women. There were no effects, beneficial or detrimental, of 
the addition of dextrose in IVF for other maternal or neonatal outcomes.  The shortening of the 
first stage of labor should be probably weighted against the trend for a higher incidence of 
neonatal hypoglycemia, which increased from 3.2% to 5.7%. Larger RCTs are probably needed 
to better evaluate effects on maternal and neonatal outcomes. 
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FIGURES 
Figure 1. Flow diagram of studies identified in the systematic review. (Prisma template 
[Preferred Reporting Item for Systematic Reviews and Meta-analyses]). 
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Figure 2. Assessment of risk of bias. (A) Summary of risk of bias for each trial; Plus sign: low 
risk of bias; minus sign: high risk of bias; question mark: unclear risk of bias. (B) Risk of bias 
graph about each risk of bias item presented as percentages across all included studies.  
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Figure 3. Forest plot for primary outcome, i.e. total length of labour from randomization to 
delivery. CI, confidence interval 
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Table 1. Characteristics of the included trials 
 Study 
Location 
GA at 
randomization (in 
weeks) 
Spontaneous 
vs IOL 
Cervical 
dilatation at 
enrollment 
(cm) 
Exclusion criteria 
Morton et al, 
1985 
United 
Kingdom 
37+0 to 42+0 Both 3-5 Patients likely to give 
birth within 2h of 
start of IVF 
Loong et al, 
1987 
China >37+0 Both NR Significant 
complications during 
pregnancy, DM, IUGR 
Piquard et al, 
1989 
France 38+0 to 41+0 Both NR DM, liver disease, 
kidney disease, or 
GDM 
Omigbodun et 
al, 1991 
Nigeria 37+0 Both NR HTN, preeclampsia, 
DM, jaundice, anemia 
Omigbodun et 
al, 1993 
Nigeria >37+0 IOL NR Rhesus positive blood 
group, HTN, DM, 
pyrexia, jaundice, 
anemia 
Nordstrom et 
al, 1995 
Singapore 37+0 to 40+4 Spontaneous 4-6 GDM, previous infant 
>4000 g, glucosuria, 
polyhydramnios, or 
excessive fetal growth 
Fisher and 
Huddleston 
1997 
United 
States 
37+0 to 42+0 Spontaneous >4 Preeclampsia, IUGR, 
initial cervical 
dilatation >9 cm, 
shoulder dystocia, 
OVD or CD, IVF 
exposure of <1h, 
abnormal 1h glucose 
screening at 24-28 
weeks, abnormal fetal 
HR tracings, non-
vertex presentation 
Jamal et al, 
2007 
Iran 37+0 to 40+6 NR 4 Pre-eclampsia, IUGR, 
dilatation >9 cm, OVD 
or CD, IVF lasting <1h, 
abnormal 1h glucose 
screening 
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 Study 
Location 
GA at 
randomization (in 
weeks) 
Spontaneous 
vs IOL 
Cervical 
dilatation at 
enrollment 
(cm) 
Exclusion criteria 
Shrivastava et 
al, 2009 
United 
States 
36+0 Spontaneous 3-5 DM, IOL, pre-
eclampsia, cardiac 
disease, renal disease, 
previous CD, 
chorioamnionitis, 
pyelonephritis, febrile 
illness before random 
assignment 
Sharma et al, 
2012 
India 36+0 Spontaneous 3-5 IOL, DM, pre-
eclampsia, cardiac or 
renal disease, 
evidence of 
chorioamnionitis or 
fetal distress, pyrexia, 
intrauterine fetal 
death, planned CD 
and use of epidural 
analgesia 
Rad et al, 
2012 
Iran NR NR 3-4 Preterm labor, 
polyhydramnios, pre-
eclampsia, IUGR, 3rd 
trimester bleeding, 
abnormal 1h glucose 
screening between 
24-28 weeks, 
maternal height <150 
cm, BMI in 1st 
trimester >26kg/m2 
Dapuzzo-
Argiriou et al, 
2016 
United 
States 
36+0 Spontaneous <6 Contraindication to 
SVD, IOL, DM or other 
glucose dysregulation 
condition, concurrent 
use of steroids, active 
labor with cervical 
dilation of ≥6 cm, or 
participation in 
another research 
study 
Garmi et al, 
2017 
Israel 37+0 Both 1 HTN disorder, DM, 
cardiac disease, major 
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 Study 
Location 
GA at 
randomization (in 
weeks) 
Spontaneous 
vs IOL 
Cervical 
dilatation at 
enrollment 
(cm) 
Exclusion criteria 
fetal malformations, 
maternal fever upon 
admission, cervical 
dilatation >9 cm at 
randomization, non-
vertex presentation, 
or any other 
contraindication to a 
trial of labor; women 
who had IVF infusion 
lasting less than 1h 
from inclusion to 
delivery were 
excluded from final 
analysis 
Fong et al, 
2017 
United 
States 
NR Spontaneous 3-5 IOL, dilation >5 cm, 
IUGR, BMI ≥50, DM, 
preeclampsia, renal 
disease, any active 
infection 
Paré et al, 
2017 
Canada >37+0 IOL 3-5 Diagnosed with GDM 
and pre-gestational 
DM, preeclampsia, 
renal disease, 
maternal heart 
disease 
Shafaie et al, 
2017 
Iran 38+0 to 41+0 Spontaneous 4 IOL, gestational HTN, 
nonreassuring fetal 
status, DM, 
preeclampsia, 
gestational DM, IUGR, 
chorioamnionitis, 
fetal distress, IFD, 
epidural, professional 
athletes 
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Table 2. Characteristics of IVF in the included trials  
 
 Number of 
participants 
dextrose 
Number of 
participants 
no dextrose 
Type of 
dextrose fluid 
used 
IVF type – 
control 
without 
dextrose 
Rate of 
IVF 
(mL/h) 
IVF 
initiated 
in latent 
vs active 
labor 
PO 
intake 
allowed 
Morton et 
al, 1985 
20  
(10 with 5%; 
10 with 10%) 
20 (10 with 
normal saline 
and 10 with 
LR solution 
5% dextrose 
10%dextrose* 
NS; LR 1 L over 
1 hour, 
then 
slow NS 
infusion  
NR NR 
Loong et 
al, 1987 
16 32 (16 with LR 
and 16 with 
nothing) 
5% dextrose in 
oxytocin 
LR and no 
IVF 
administe
red 
Dextros
e: 20-
240; 
LR: 80-
120 
NR NPO 
Piquard et 
al, 1989 
59 66 10% dextrose in 
water 
LR 300 Active NR 
Omigbodu
n et al, 
1991 
36 34 5% dextrose in 
water 
NS NR NR Unrestric
ted 
Omigbodu
n et al, 
1993 
40 42 5% dextrose in 
water 
NS NR Both Unrestric
ted 
Nordstro
m et al, 
1995 
12 11 5% dextrose* NS 180 Active NPO  
Fisher and 
Huddlesto
n 1997 
43 48 5% dextrose in 
LR 
LR 125 Active NR 
Jamal et 
al, 2007 
89 89 5% dextrose in 
NS 
LR 120 Active NR 
Shrivastav
a et al, 
2009 
192  
(94 with 5%; 
98 with 10%) 
97 5% dextrose in 
NS; 10% 
dextrose in NS 
NS 125 Active Ice chips 
or NPO 
Sharma et 
al, 2012 
125 125 5% dextrose in 
NS 
NS 175 Active Ice chips 
or NPO 
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 Number of 
participants 
dextrose 
Number of 
participants 
no dextrose 
Type of 
dextrose fluid 
used 
IVF type – 
control 
without 
dextrose 
Rate of 
IVF 
(mL/h) 
IVF 
initiated 
in latent 
vs active 
labor 
PO 
intake 
allowed 
Rad et al, 
2012 
43 54 5% dextrose in 
NS 
NS 120 Active NPO 
Dapuzzo-
Argiriou et 
al, 2016 
153 156 5% dextrose in  
LR 
LR 125 Active NR 
Garmi et 
al, 2017 
98 202 
(101 at 125 
mL/h;101 at 
250 mL/h) 
5% dextrose in 
NS 
LR 125 or 
250 
NR Ice chips, 
water, 
tea with 
sugar 
Fong et al, 
2017 
182 
 (92 with 5%; 
90 with 
2.5%) 
92 5% dextrose in 
NS; 2.5% 
dextrose in NS 
NS 125 or 
250 
Active Ice chips, 
sips of 
water 
Paré et al, 
2017 
96 97 5% dextrose in 
NS 
NS 250 Latent Unrestric
ted 
Shafaie et 
al, 2017 
67 67 5% dextrose 
with oral 
fluids** 
LR with 
oral 
fluids** 
125 Active Oral 
fluids** 
Abbreviations: CD, cesarean delivery; VD, vaginal delivery; IVF, intravenous fluid; NR, not reported; NS, 0.9% 
normal saline solution; LR, Lactated Ringer’s solution; PO, oral intake; NPO, no oral intake 
Number of participants presented as total 
*IVF vehicle for dextrose administration not indicated 
**Oral fluids included water, apple juice, or orange juice 
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Table 3. Descriptive labor characteristics and primary outcomes of the included trials  
 % Induced 
n/N (%) 
% Nulliparous 
n/N (%) 
Oxytocin use 
n/N (%) 
Epidural use 
n/N (%) 
Primary outcome 
Morton et al, 
1985 
NR by group; 
27/40 (67.5%) 
11/20 vs 10/20 9/20 (45%) vs 
8/20 (40%) 
NR by group; 
1/40 (2.5%) 
Intermediary 
metabolites 
Loong et al, 
1987 
NR 5/16 (3.1%) vs 
14/32 (4.4%) 
16/16 (100%) 
vs 32/32 
(100%) 
NR Maternal blood 
glucose 
Piquard et al, 
1989 
NR NR NR 3/59 (5.1%) vs 
3/66 (4.5%) 
NR 
Omigbodun et 
al, 1991 
16/36 (44.4%) 
vs 14/34 
(41.2%) 
NR 36/36 (100%) 
vs 34/34 
(100%) 
NR Sodium 
Omigbodun et 
al, 1993 
20/40 (50%) vs 
20/42 (47.6%) 
NR 40/40 (100%) 
vs 42/42 
(100%) 
NR Bilirubin 
Nordstrom et al, 
1995 
0/12 (0%) vs 
0/11 (0%) 
6/12 (50%) vs 
3/11 (27.3%) 
7/12 (58%) vs 
2/11 (18%) 
1/12 (5%) vs 
2/11 (18%) 
NR 
Fisher and 
Huddleston 
1997 
0/48 (0%) vs 
0/43 (0%) 
NR NR 20/48 (41.7%) 
vs 18/43 
(41.8%) 
UA pH 
Jamal et al, 2007 NR NR NR NR UA pH 
Shrivastava et 
al, 2009 
0/192 (0%) vs 
0/97 (0%)* 
192/192 (100%) 
vs 97/97 (100%) 
178/192 (93%) 
vs 80/97 (82%) 
149/192 
(77.6%) vs 
76/97 (80%) 
DOL 
Sharma et al, 
2012 
0/125 (0%) vs 
0/125 (0%) * 
125/125 (100%) 
vs 125/125 
(100%) 
7/125 (5.6%) vs 
23/125 (18.4%) 
0/125 (0%) vs 
0/125 (0%) 
DOL 
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 % Induced 
n/N (%) 
% Nulliparous 
n/N (%) 
Oxytocin use 
n/N (%) 
Epidural use 
n/N (%) 
Primary outcome 
Rad et al, 2012 NR 43/43 (100%) vs 
54/54 (100%) 
3/43 (7%) vs 
13/54 (24.5%) 
NR DOL 
Dapuzzo-
Argiriou et al, 
2016 
0/153 (0%) vs 
0/156 (0%)* 
83/151 (55.0%) 
vs 86/156 
(55.1%) 
92/153 (60.1%) 
vs 88/156 
(56.4%) 
NR Rate of CD  
Garmi et al, 
2017 
66/98 (67.3%) 
vs 140/202 
(69.3%) 
98/98 (100%) vs 
202/202 (100%) 
38/98 (38.8%) 
vs 81/202 
(40%) 
75/98 (76.5%) 
vs 150/202 
(74%) 
DOL 
Fong et al, 2017 0/182 (0%) vs 
0/92 (0%)* 
182/182 (100%) 
vs 92/92 (100%) 
NR NR DOL 
Paré et al, 2017 96/96 (100%) 
vs 97/97 
(100%) 
96/96 (100%) vs 
97/97 (100%) 
96/96 (100%) 
vs 97/97 
(100%) 
NR DOL 
Shafaie et al, 
2017 
0/67 (0%) vs 
0/67 (0%) 
67/67 (100%) vs 
67/67 (100%) 
7/67 (10.4%) vs 
38/67 (56.7%) 
0/67 (0%) vs 
0/67 (0%) 
Rate of CD 
Total 198/1049 
(18.9%) vs 
271/966 
(28.1%) 
897/982 (91.3%) 
vs 837/933 
(89.7%) 
504/862 
(58.5%) vs 
498/885 
(56.3%)  
247/464 
(53.2%) vs 
247/475 (52%) 
N/A 
I2 0% 0% 88% 0% N/A 
RR or MD (95% 
CI) 
0.99 [0.66, 
1.48] 
 
0.94 [0.61, 1.43] 
 
0.68 [0.29, 
1.58] 
 
 
1.04 [0.73, 
1.48] 
 
N/A 
Abbreviations: NR, not reported; CD, cesarean delivery; UA, umbilical artery; DOL, duration of labor; N/A, not 
applicable; RCT, randomized controlled trial  
Data are presented as dextrose n/N (%) vs control IVF n/N (%) 
*Represents an exclusion criteria from the RCT 
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Table 4. Primary outcomes and secondary labor outcomes 
 Total length of 
labor 
(min±SD) 
Length 1st stage 
labor (min±SD) 
Length 2nd 
stage labor 
(min±SD) 
% 
prolonged 
labor 
(>12h) 
Chorioamnionitis 
n/N (%) 
Postpartum 
Hemorrhage 
n/N (%) 
Morton et 
al, 1985 
NR NR NR NR NR NR 
Loong et al, 
1987 
NR NR NR NR NR NR 
Piquard et 
al, 1989 
NR NR 23.5±17.4 vs 
17.6±12.3 
NR NR NR 
Omigbodun 
et al, 1991 
556±156.7 vs 
574±174.3 
NR NR NR NR NR 
Omigbodun 
et al, 1993 
570±152 vs 
576±164 
NR NR NR NR NR 
Nordstrom 
et al, 1995 
361.7±156.2 
vs 
344.1±218.21 
NR NR NR NR NR 
Fisher and 
Huddleston 
1997 
NR NR NR NR NR NR 
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 Total length of 
labor 
(min±SD) 
Length 1st stage 
labor (min±SD) 
Length 2nd 
stage labor 
(min±SD) 
% 
prolonged 
labor 
(>12h) 
Chorioamnionitis 
n/N (%) 
Postpartum 
Hemorrhage 
n/N (%) 
Jamal et al, 
2007 
NR NR NR NR NR NR 
Shrivastava 
et al, 2009 
NR NR NR 12/148 
(8%) vs 
18/84 
(22%) 
28/192 (14.6%) 
vs 7/97 (7%) 
12/192 
(6.3%) vs 
5/97 (5.2%) 
Sharma et 
al, 2012 
297.8±154.4 
vs 
473.8±220.5 
NR NR 4/125 
(3.2%) vs 
15/125 
(12%) 
3/125 (2.4%) vs 
8/125 (6.4%) 
NR 
Rad et al, 
2012 
NR 163.73±39.5 vs 
291.5±89.3 
33.12±10.48 
vs 
58.88±33.58 
NR NR NR 
Dapuzzo-
Argiriou et 
al, 2016 
820±473 vs 
831±484 
710±433 vs. 
734±453 
73±105 vs 
82±154 
NR 5/150 (3.3%) vs 
6/152 (3.9%) 
2/149 
(1.3%) vs 
9/151 
(6.0%) 
Garmi et al, 
2017 
629.95±325.11 
vs 
571.9±309.5 
NR 88.4±69.16 vs 
96.16±76.55 
28/98 
(28.6%) vs 
50/202 
(24.8%) 
NR 5/98 (5.1%) 
vs 14/202 
(6.9%) 
Fong et al, 
2017 
593.86± 
368.955 vs 
607.64± 
358.586 
486.66±346.207 
vs 
509.63±345.139 
106.90±94.208 
vs 
98.01±67.286 
36/132 
(27.3%) vs 
23/73 
(31.5%) 
30/182 (16.5%) 
vs 15/92 (16.3%) 
NR 
Paré et al, 
2017 
423±35.3 vs 
499±25.8  
320±22.8 vs 
390±37.0 
80±9.6 vs 
95±15.3 
NR NR NR 
Shafaie et 
al, 2017 
NR NR NR 2/67 (3%) 
vs 5/67 
(7.5%) 
0/67 (0%) vs 
0/67 (0%) 
NR 
Total N/A  N/A N/A 82/570 
(14.4%) vs 
111/551 
(20.1%) 
66/716 (9.2%) vs 
36/533 (6.8%) 
19/439 
(4.3%) vs 
28/450 
(6.2%) 
I2 82% 84% 91% 66% 44% 40% 
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 Total length of 
labor 
(min±SD) 
Length 1st stage 
labor (min±SD) 
Length 2nd 
stage labor 
(min±SD) 
% 
prolonged 
labor 
(>12h) 
Chorioamnionitis 
n/N (%) 
Postpartum 
Hemorrhage 
n/N (%) 
RR or MD 
(95% CI) 
-38.33 [-88.23, 
11.57] 
 
 
-75.81 [-120.67, 
-30.95] 
 
 
-7.63 [-19.80, 
4.54] 
 
0.56 
[0.30, 
1.07] 
 
1.03 [0.54, 1.96] 
 
 
0.66 [0.27, 
1.61] 
 
 
Abbreviations: NR, not reported; CD, cesarean delivery; N/A, not applicable. Boldface data, statistically significant 
Data are presented as dextrose n/N (%) vs control IVF n/N (%) or as dextrose mean±SD vs control IVF mean±SD 
 
 
 
 
 
 
 
Table 5. Mode of delivery  
Reference Spontaneous VD 
n/N (%) 
Operative VD 
(vacuum or 
forceps) 
n/N (%) 
CD rate  
n/N (%) 
CD indicated 
for labor 
dystocia  
n/N (%) 
CD indicated 
for fetal well-
being  
n/N (%) 
Morton et al, 
1985 
7/20 (35%) vs 
6/20 (30%) 
NR NR NR NR 
Loong et al, 1987 NR NR NR NR NR 
Piquard et al, 
1989 
47/59 (79.7%) vs 
53/66 (80.3%) 
8/59 (13.6%) vs 
12/66 (18.2%) 
4/59 (6.8%) vs 
12/66 (18.2%) 
NR NR 
Omigbodun et al, 
1991 
NR NR NR NR NR 
Omigbodun et al, 
1993 
34/40 (85%) vs 
36/42 (85.7%) 
0/40 (0%) vs 0/42 
(0%) 
6/40 (15%) vs 
6/42 (14%) 
NR NR 
Nordstrom et al, 
1995 
9/12 (75%) vs 
10/11 (90.9%) 
1/11 (9.1%) vs 
0/12 (0%) 
2/12 (16.7%) 
vs 1/11 (9.1%) 
1/12 (8.3%) vs 
2/11 (18.2%) 
1/12 (8.3%) vs 
0/11 (0%) 
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Reference Spontaneous VD 
n/N (%) 
Operative VD 
(vacuum or 
forceps) 
n/N (%) 
CD rate  
n/N (%) 
CD indicated 
for labor 
dystocia  
n/N (%) 
CD indicated 
for fetal well-
being  
n/N (%) 
Fisher and 
Huddleston 1997 
43/43 (100%) vs 
48/48 (100%) 
0/43 (0%) vs 0/48 
(0%) 
0/43 (0%) vs 
0/48 (0%) 
N/A N/A 
Jamal et al, 2007 NR * NR N/A N/A 
Shrivastava et al, 
2009 
127/192 (66.1%) 
vs 69/97 (71.1%) 
22/192 (11.5%) 
vs 13/97 (13.4%) 
42/192 
(21.9%) vs 
14/97 (14%) 
28/192 
(14.6%) vs 
12/97 (12.4%) 
10/192 (5.2%) 
vs 2/97 (2.1%) 
Sharma et al, 
2012 
112/125 (89.6%) 
vs 104/125 
(83.2%) 
10/125 (8%) vs 
17/125 (13.6%) 
3/125 (2.4%) 
vs 4/125 
(3.2%) 
2/125 (1.6%) 
vs 0/125 (0%) 
1/125 (0.8%) 
vs 3/125 
(2.4%) 
Rad et al, 2012 42/43 (97.7%) vs 
51/54 (94.4%) 
NR 1/43 (2.3%) vs 
3/54 (5.6%) 
0/43 (0%) VS 
2/54 (3.7%) 
1/43 (2.3%) vs 
1/54 (1.9%) 
Dapuzzo-Argiriou 
et al, 2016 
122/153 (79.7%) 
vs 131/156 
(84.0%) 
8/153 (5.2%) vs. 
7/156 (4.5%) 
23/153 (15%) 
vs 18/156 
(11.5%) 
NR NR 
Garmi et al, 2017 81/98 (82.7%) vs 
155/202 (76.76%) 
6/98 (6.1%) vs 
23/202 (11.4%) 
11/98 (11.2%) 
vs 24/202 
(11.9%) 
NR NR 
Fong et al, 2017 117/182 (64.3%) 
vs 68/92 (73.9%) 
15/182 (8.2%)vs 
5/92 (5.4%) 
50/182 
(27.5%) vs 
19/92 (20.7%) 
36/182 
(19.8%) vs 
14/92 (15.2%) 
13/182 (7.1%) 
vs 5/92 (5.4%) 
Paré et al, 2017 49/96 (51%) vs 
46/97 (47.4%) 
20/96 (20.8%) vs 
29/97 (29.9%) 
27/96 (28.1%) 
vs 22/97 
(22.7%) 
NR NR 
Shafaie et al, 
2017 
65/67 (97%) vs 
63/67 (94%) 
0/67 (0%) vs 0/67 
(0%) 
2/67 (3%) vs 
4/67 (6%) 
NR NR 
Total 775/1032 (75.1%) 
vs 685/875 
(78.3%) 
181/1024 
(17.7%) vs 
106/955 (11.1%) 
129/875 
(14.7%) vs 
113/912 
(12.4%) 
67/554 
(12.1%) vs 
30/379 (7.9%) 
26/554 (4.7%) 
vs 11/379 
(2.9%) 
I2 0% 92% 0% 0% 0% 
RR or MD (95% 
CI) 
0.93 [0.73, 1.18] 
 
 
1.46 [0.46, 4.59] 
 
 
1.10 [0.82, 
1.48] 
 
1.24 [0.77, 
1.98] 
 
1.40 [0.65, 
3.00] 
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Reference Spontaneous VD 
n/N (%) 
Operative VD 
(vacuum or 
forceps) 
n/N (%) 
CD rate  
n/N (%) 
CD indicated 
for labor 
dystocia  
n/N (%) 
CD indicated 
for fetal well-
being  
n/N (%) 
     
Abbreviations: NR, not reported; VD, vaginal delivery; CD, cesarean delivery. Boldface data, statistically significant 
Data are presented as dextrose n/N (%) vs control IVF n/N (%) 
*Category represents an exclusion criterion for the trial 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Prespecified neonatal outcomes 
 5 min Apgar <7 
n/N (%) 
Hypoglycemia 
n/N (%) 
Admission to NICU 
n/N (%) 
BW 
(g±SD) 
Morton et al, 1985 NR NR NR NR 
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 5 min Apgar <7 
n/N (%) 
Hypoglycemia 
n/N (%) 
Admission to NICU 
n/N (%) 
BW 
(g±SD) 
Loong et al, 1987 NR NR NR NR 
Piquard et al, 1989 0/59 (0%) vs 0/66 
(0%) 
0/59 (0%) vs 0/66 
(0%) 
NR 3470±494 vs 
3335±532 
Omigbodun et al, 
1991 
NR NR NR 3230±390 vs 
3230±360 
Omigbodun et al, 
1993 
NR NR NR 3270±420 vs 
3210±360 
Nordstrom et al, 
1995 
0/12 (0%) vs 0/11 
(0%) 
1/12 (8.3%) vs 2/11 
(18.2%) 
0/12 (0%) vs 0/11 
(0%) 
2982±345 vs 
3257±394 
Fisher and 
Huddleston 1997 
0/43 (0%) vs 0/48 
(0%) 
NR NR 3300±500 vs 
3200±400 
Jamal et al, 2007 0/89 (0%) vs 0/89 
(0%) 
0/89 (0%) vs 0/89 
(0%) 
NR NR 
Shrivastava et al, 
2009 
3/192 (1.6%) vs 
1/97 (0.3%) 
4/192 (2.1%) vs 1/97 
(1%) 
16/192 (8.3%) vs 
8/97 (2.8%) 
NR 
Rad et al, 2012 NR NR NR NR 
Sharma et al, 2012 NR NR NR NR 
Dapuzzo-Argiriou et 
al, 2016 
4/153 (2.6%) vs 
0/155 (0%) 
18/55 (32.7%) vs 
7/50 (14.0%) 
17/153 (11.1%) vs 
19/156 (12.2%) 
3408±417 vs 
3428±404 
Garmi et al, 2017 0/98 (0%) vs 
1/202 (0.5%) 
NR NR NR 
Fong et al, 2017 2/182 (1.1%) vs 
1/92 (1.1%)  
NR 48/182 (26.4%) vs 
20/92 (21.7%)  
NR 
Paré et al, 2017 NR NR NR 3405±493 vs 
3491±490 
Shafaie et al, 2017 NR NR NR NR 
Total 9/785 (1.1%) vs 
3/712 (0.4%) 
23/407 (5.7%) vs 
10/313 (3.2%) 
81/539 (15%) vs 
47/356 (13.2%) 
N/A 
I2 0% 2% 0% 30% 
RR or MD (95% CI) 1.70 [0.46, 6.33] 
 
 
2.25 [0.94, 5.35] 
 
 
1.09 [0.73, 1.63] 
 
 
1.27 [-71.12, 73.67] 
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Abbreviations: NR, not reported; UA, umbilical artery; UV, umbilical vein; RR, relative risk; GA, gestational age; IVF, 
intravenous fluid; BW, birthweight; R/O, rule out; CD, Cesarean delivery 
Data are presented as dextrose n/N (%) vs control IVF n/N (%) or as dextrose mean±SD vs control IVF mean±SD 
 
 
 
 
Table 7. Neonatal umbilical blood gas outcomes at delivery 
Reference UA cord pH 
(pH±SD) 
(mean 7.27; 5th to 
95th percentile 
7.15-7.38)* 
UA pCO2 
(mmHg±SD) 
(mean 50.3; 5th to 
95th percentile 32-
68)* 
UA pO2 (mmHg±SD) 
 
(mean 18.4; 5th to 
95th  
 
percentile 9-32)* 
UA Base deficit 
(mEq/L±SD) 
(mean -2.7; 5th to 
95th  
 
percentile -8.1-0.9)* 
Morton et al, 1985 NR NR NR NR 
Loong et al, 1987 NR NR NR NR 
Piquard et al, 1989 7.19±0.06 vs 
7.24±0.07 
52.9±6.8 vs 
47.4±7.4 
17.0±5.3 vs 
16.8±5.4 
-5.9±2.1 vs -5.7±2.6 
Omigbodun et al, 
1991 
NR NR NR NR 
Omigbodun et al, 
1993 
NR NR NR NR 
Nordstrom et al, 
1995 
7.25±0.07 vs 
7.28±0.08 
 
46.50±4.50 vs 
43.50±3.00 
18.75±4.5 vs 
16.50±5.25 
6.0±3.3 vs 5.0±3.9 
Fisher and 
Huddleston 1997 
7.30±0.07 vs 
7.27±0.09 
44.8±9.9 vs 
50.6±12.9 
NR -4.5±3.1 vs -5.0±2.5 
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Reference UA cord pH 
(pH±SD) 
(mean 7.27; 5th to 
95th percentile 
7.15-7.38)* 
UA pCO2 
(mmHg±SD) 
(mean 50.3; 5th to 
95th percentile 32-
68)* 
UA pO2 (mmHg±SD) 
 
(mean 18.4; 5th to 
95th  
 
percentile 9-32)* 
UA Base deficit 
(mEq/L±SD) 
(mean -2.7; 5th to 
95th  
 
percentile -8.1-0.9)* 
Jamal et al, 2007 7.28±0.06 vs 
7.25±0.07 
41.6±4.1 vs 
44.8±5.6 
NR -6.6±1.8 vs -7.3±2.1 
Shrivastava et al, 
2009 
NR NR NR NR 
Sharma et al, 2012 NR NR NR NR 
Rad et al, 2012 NR NR NR NR 
Dapuzzo-Argiriou 
et al, 2016 
7.22±0.08 vs. 
7.24±0.07 
55±11.4 vs 
54.8±11.1 
20.3±8.8 vs 
21.1±20.0 
NR 
Garmi et al, 2017 NR NR NR NR 
Fong et al, 2017 NR NR NR NR 
Paré et al, 2017 7.21±0.7 vs 
7.22±0.7 
NR NR NR 
Shafaie et al, 2017 NR NR NR NR 
Total N/A N/A N/A N/A 
I2 71% 92% 0% 12% 
RR or MD (95% 
CI) 
0.00 [-0.02, 0.02] 
 
0.07 [-4.22, 4.35] 
 
 
0.50 [-1.12, 2.12] 
 
 
0.40 [-0.09, 0.88] 
 
 
Abbreviations: NR, not reported; UA, umbilical artery; N/A, not applicable  
Data are presented as dextrose mean±SD vs control IVF mean±SD 
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*Reference values are from Riley RJ, Johnson JWC. Collecting and analyzing cord blood gases. Clin Obstet Gynecol 
1993; 36:13 (Reference #23) 
 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
